Contineum Therapeutics, Inc. SEC filings CTNM
Contineum Therapeutics, Inc. has 201 filings in SEC EDGAR's recent list, going back to Dec 13, 2023. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2026 | Jun 26, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 30, 2026 | Apr 30, 2026 |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| 424B5 | Prospectus supplement | Mar 5, 2026 | — |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 26, 2026 | Jan 23, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 15, 2025 | Dec 11, 2025 |
| 424B5 | Prospectus supplement | Dec 12, 2025 | — |
| 424B5 | Prospectus supplement | Dec 11, 2025 | — |
| 8-K |
Current report
Other events
|
Dec 11, 2025 | Dec 8, 2025 |
| 8-K |
Current report
Other events
|
Nov 20, 2025 | Nov 20, 2025 |
| 10-Q | Quarterly report | Oct 30, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Oct 30, 2025 | Oct 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 18, 2025 | Sep 18, 2025 |
| 10-Q | Quarterly report | Aug 5, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2025 | Aug 5, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2025 | Jun 26, 2025 |
| EFFECT | Filing | May 23, 2025 | — |
| CORRESP | Letter to the SEC | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| S-8 | Employee stock plan registration | May 14, 2025 | — |
| 8-K |
Current report
Results of operations, Other events
|
May 14, 2025 | May 14, 2025 |
| S-3 | Shelf registration | May 14, 2025 | — |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Other events
|
Apr 28, 2025 | Apr 28, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 17, 2025 | Mar 14, 2025 |
| S-8 | Employee stock plan registration | Mar 6, 2025 | — |
| 10-K | Annual report | Mar 6, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2025 | Mar 6, 2025 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K/A |
Amended current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 24, 2024 | Jun 21, 2024 |
| 8-K |
Current report
Officer or director change
|
May 31, 2024 | May 24, 2024 |
| 8-K |
Current report
Officer or director change
|
May 20, 2024 | May 20, 2024 |
| 10-Q | Quarterly report | May 16, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 16, 2024 | May 16, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 9, 2024 | Apr 9, 2024 |
| S-8 | Employee stock plan registration | Apr 9, 2024 | — |
| 424B4 | Prospectus | Apr 8, 2024 | — |
| SEC STAFF LETTER | Filing | Apr 5, 2024 | — |
| EFFECT | Filing | Apr 4, 2024 | — |
| CERT | Filing | Apr 4, 2024 | — |
| 8-A12B | Filing | Apr 2, 2024 | — |
| CORRESP | Letter to the SEC | Apr 2, 2024 | — |
| CORRESP | Letter to the SEC | Apr 2, 2024 | — |
| S-1/A | Amended registration statement | Apr 1, 2024 | — |
| CORRESP | Letter to the SEC | Mar 21, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| S-1 | Registration statement | Mar 15, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2024 | — |
| DRSLTR | Filing | Feb 15, 2024 | — |
| DRS/A | Filing | Feb 15, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2024 | — |
| DRSLTR | Filing | Jan 29, 2024 | — |
| DRS/A | Filing | Jan 29, 2024 | — |
| SEC STAFF LETTER | Filing | Jan 25, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 11, 2024 | — |
| DRS | Filing | Dec 13, 2023 | — |
Showing 76 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTNM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1855175
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.